Recordati : Back in the rare diseases game in 2019 ?
>Résultats 2018 en ligne avec les attentes - Hier à la mi-journée, Recordati a publié ses résultats préliminaires FY 2018. Contrat rempli pour le management qui publie des chiffres conformes à la guidance voire légèrement mieux que cette dernière. Les chiffres publiés ressortent en ligne avec nos attentes et celles du consensus : des ventes de 1 352 M€ (+5%), un EBITDA de 499 M€ (+10%), un EBIT de 442 M€ (+9%) et un RN de 312 M€ (+8%). La dette nette ressort à 588 M€ ...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.